BioLineRx (TASE:BLRX) - 주가, 뉴스 및 분석

BLRX 주식 개요

상용 단계의 바이오 제약 회사인 바이오라인알엑스는 종양학 및 희귀 질환 치료제를 개발 및 상용화하는 회사입니다. 자세한 내용

BLRX 기본 분석
눈송이 점수
가치 평가	5/6
미래 성장	2/6
과거 실적	0/6
재무 상태	5/6
배당금	0/6

보상

공정 가치 추정치보다 낮은 95.4% 에서 거래

수익은 연간 27.76% 증가할 것으로 예상됩니다.

동종업계 및 업계 대비 좋은 가치로 거래

위험 분석

최근 3개월간 주가 변동폭 심해

현재 수익성이 없으며 향후 3년 동안 수익을 낼 것으로 예상되지 않습니다.

지난 1년 동안 주주가 희석되었습니다.

의미 있는 시가총액이 없습니다. ( ₪90M )

BioLineRx Ltd. 경쟁사

Evogene

TASE:EVGN

₪31.7m

PlantArc Bio

TASE:PLNT

₪4.4m

Can-Fite BioPharma

TASE:CANF

₪53.1m

Kamada

TASE:KMDA

₪1.2b

가격 내역 및 성능

다음에 대한 모든 사상 최고가, 변동 및 가격 하락 요약 BioLineRx
과거 주가
현재 주가	₪0.075
52주 최고치	₪0.44
52주 최저치	₪0.072
베타	0.87
11개월 변경	-42.31%
3개월 변경 사항	-58.79%
1년 변경 사항	-80.47%
33년 변화	-86.09%
5년 변화	-87.84%
IPO 이후 변화	-99.89%

최근 뉴스 및 업데이트

Recent updates

주주 수익률

	BLRX	IL Biotechs	IL 마켓
7D	-39.0%	-7.3%	1.6%
1Y	-80.5%	-13.0%	25.8%

수익률 대 산업: BLRX 지난 1년 동안 -13 %를 반환한 IL Biotechs 업계보다 저조한 성과를 냈습니다.

수익률 대 시장: BLRX 지난 1년 동안 25.8 %를 반환한 IL 시장보다 저조한 성과를 냈습니다.

가격 변동성

Is BLRX's price volatile compared to industry and market?
BLRX volatility
BLRX Average Weekly Movement	11.0%
Biotechs Industry Average Movement	4.9%
Market Average Movement	4.1%
10% most volatile stocks in IL Market	7.3%
10% least volatile stocks in IL Market	2.9%

안정적인 주가: BLRX 의 주가는 지난 3개월 동안 변동성이 심했습니다.

시간에 따른 변동성: BLRX 의 주간 변동성( 11% )은 지난 1년 동안 안정적이었지만 여전히 IL 의 75%보다 높습니다. 주식.

회사 소개

설립	직원	CEO	웹사이트
2003	79	Phil Serlin	www.biolinerx.com

바이오라인알엑스는 상업화 단계의 바이오 제약 회사로 종양 및 희귀 질환 치료제를 개발 및 상업화하고 있습니다. 이 회사의 파이프라인에는 겸상 적혈구 질환 치료를 위한 임상 1상 및 췌장암 치료를 위한 임상 2b상 중인 펩타이드 아펙다(모틱사포르타이드)와 다발성 골수종 치료를 위한 임상 3상을 완료한 펩타이드 아펙다(모틱사포르타이드)가 있습니다. 또한 피부 병변의 비수술적 제거를 위한 산성 수용액을 함유한 펜 형태의 어플리케이터인 BL-5010을 개발하고 있습니다.

BioLineRx Ltd. 기본 사항 요약

BioLineRx 의 수익과 매출은 시가총액과 어떻게 비교하나요?
BLRX 기본 통계
시가총액	₪89.99m
수익(TTM)	-₪109.93m
수익(TTM)	₪62.22m

1.4x

P/S 비율

-0.8x

P/E 비율

BLRX 주가가 과대평가되어 있나요?

공정 가치 및 가치 분석 보기

수익 및 수익

최신 수익 보고서의 주요 수익성 통계(TTM)
BLRX 손익 계산서(TTM)
수익	US$17.05m
수익 비용	US$6.04m
총 이익	US$11.00m
기타 비용	US$41.12m
수익	-US$30.12m

최근 보고된 수익

Jun 30, 2024

다음 수익 날짜

n/a

주당 순이익(EPS)	-0.025
총 마진	64.55%
순이익 마진	-176.67%
부채/자본 비율	210.6%

BLRX 의 장기적인 성과는 어땠나요?

과거 실적 및 비교 보기

BLRX 주식 개요

보상

위험 분석

BioLineRx Ltd. 경쟁사

TASE:EVGN

₪31.7m

TASE:PLNT

₪4.4m

TASE:CANF

₪53.1m

TASE:KMDA

₪1.2b

가격 내역 및 성능

최근 뉴스 및 업데이트

BioLineRx Ltd. has filed a Follow-on Equity Offering in the amount of $8.998765 million.

BioLineRx Ltd. to Report Q3, 2024 Results on Nov 25, 2024

Biolinerx Announces Oral Presentation on Data from Phase 1 Clinical Trial Evaluating Motixafortide for Cd34+ Hematopoietic Stem Cell Mobilization for Gene Therapies in Sickle Cell Disease At Ash 2024

BioLineRx Ltd. Announces USPTO Allowance of New Composition of Matter Patent on Motixafortide

New major risk - Revenue and earnings growth

BioLineRx Ltd., Annual General Meeting, Oct 01, 2024

Recent updates

BioLineRx Ltd. has filed a Follow-on Equity Offering in the amount of $8.998765 million.

BioLineRx Ltd. to Report Q3, 2024 Results on Nov 25, 2024

Biolinerx Announces Oral Presentation on Data from Phase 1 Clinical Trial Evaluating Motixafortide for Cd34+ Hematopoietic Stem Cell Mobilization for Gene Therapies in Sickle Cell Disease At Ash 2024

BioLineRx Ltd. Announces USPTO Allowance of New Composition of Matter Patent on Motixafortide

New major risk - Revenue and earnings growth

BioLineRx Ltd., Annual General Meeting, Oct 01, 2024

BioLineRx Ltd. to Report Q2, 2024 Results on Aug 15, 2024

BioLineRx Ltd Announces Clinical Trial Agreement with St. Jude Children's Research Hospital, Inc. to Evaluate Motixafortide for CD34+ Hematopoietic Stem Cell Mobilization For Gene Therapy Applications in Sickle Cell Disease

New major risk - Financial position

BioLineRx Ltd. Announces Abstract on Pilot Study Data from Phase 2 Combination Clinical Trial Evaluating Motixafortide in First-Line Pancreatic Cancer at American Society of Clinical Oncology

BioLineRx Ltd. to Report Q1, 2024 Results on May 28, 2024

BioLineRx Announces Receipt of Nasdaq Minimum Bid Price Notification

BioLineRx Ltd. Announces Poster Presentation on Apheresis Center Efficiency and CXCR4 Antagonists Including APHEXDA® (Motixafortide) in Patients with Multiple Myeloma at the ASFA 2024 Annual Meeting

Does BioLineRx (TLV:BLRX) Have A Healthy Balance Sheet?

New major risk - Share price stability

New major risk - Revenue and earnings growth

BioLineRx Ltd. to Report Fiscal Year 2023 Results on Mar 26, 2024

BioLineRx Strengthens Intellectual Property Estate with Notice of Allowance for U.S. Patent Covering Method of Manufacturing Motixafortide (Bl-8040) Suitable for Large Scale Production

Biolinerx Announces First Patient Dosed in Randomized Phase 2 Combination Clinical Trial Evaluating Motixafortide in First-Line Pancreatic Cancer

BioLineRx Ltd. Announces Acceptance of Two Poster Presentations on APHEXDA®? (Motixafortide) for CD34+ Hematopoietic Stem Cell (HSC) Mobilization in Patients with Multiple Myeloma at the 2024 Tandem Meetings of ASTCT®?

New minor risk - Market cap size

BioLineRx Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating Motixafortide for CD34+ Hematopoietic Stem Cell Mobilization for Gene Therapies in Sickle Cell Disease

BioLineRx Ltd. Appoints Gal Cohen to Its Board as a Class I Director

New major risk - Shareholder dilution

BioLineRx Ltd. to Report Q3, 2023 Results on Nov 20, 2023

New minor risk - Shareholder dilution

BioLineRx Ltd. announced that it has received $14.6 million in funding

New minor risk - Market cap size

Biolinerx Ltd. Announces Encouraging Data from Pilot Phase of Phase 2 Combination Clinical Trial with Motixafortide in First-Line Pancreatic Cancer (Pdac)

BioLineRx Ltd Announces FDA Approval of APHEXDA™ (motixafortide) in Combination with Filgrastim (G-CSF) to Mobilize Hematopoietic Stem Cells for Collection and Subsequent Autologous Transplantation in Patients with Multiple Myeloma

New major risk - Financial position

BioLineRx (TLV:BLRX) Has Debt But No Earnings; Should You Worry?

BioLineRx Ltd. to Report Q2, 2023 Results on Aug 30, 2023

BioLineRx Ltd. Announces Initiation of Randomized Phase 2 Clinical Trial in First Line Metastatic Pancreatic Cancer Based on Preliminary Data from Single-Arm Pilot Phase

BioLineRx Ltd., Annual General Meeting, Aug 07, 2023

BioLineRx Ltd. to Report Q1, 2023 Results on May 24, 2023

Health Check: How Prudently Does BioLineRx (TLV:BLRX) Use Debt?

Rosen Law Firm Encourages Biolinerx Ltd. Investors with Losses to Secure Counsel Before Important Deadline

Rosen Law Firm Files Securities Class Action Lawsuit on Behalf of BioLineRx Ltd

BioLineRx Ltd. Appoints Tami Rachmilewitz, M.D., as Chief Medical Officer

BioLineRx Ltd. Announces Results from Phase 1/2a Study of Investigational Anti-Tumor Vaccine AGI-134 in Metastatic Solid Tumors

Less than half of directors are independent

BioLineRx Ltd. Announces U.S. FDA Acceptance of New Drug Application for Aphexda® (Motixafortide) in Stem Cell Mobilization

BioLineRx Announces Receipt of Nasdaq Minimum Bid Price Notification

Biolinerx Ltd. Announces U.S. Commercialization Plan for Aphexda (Motixafortide) in Stem Cell Mobilization

BioLineRx Announces Submission of New Drug Application to U.S. Food and Drug Administration for Motixafortide in Stem Cell Mobilization

BioLineRx Ltd. to Report Q2, 2022 Results on Aug 16, 2022

BioLineRx Ltd. Appoints Holly W. May as its Chief Commercial Officer

Is BioLineRx (TLV:BLRX) A Risky Investment?

BioLineRx Ltd., Annual General Meeting, Jul 03, 2022

BioLineRx Ltd. to Report Q1, 2022 Results on May 11, 2022

Less than half of directors are independent

BioLineRx Ltd. Announces Additional Positive Results from Pharmacoeconomic Study Comparing Motixafortide + G-CSF to Plerixafor + G-CSF in Stem Cell Mobilization

Is BioLineRx (TLV:BLRX) Using Debt In A Risky Way?

BioLineRx Announces Completion of Enrollment of Phase 1/2A Study of Innovative Intratumoral Cancer Vaccine, AGI-134, in Unresectable Metastatic Solid Tumors

BioLineRx Ltd. Announces Successful Completion of Pre-NDA Meeting with FDA for Motixafortide for Stem Cell Mobilization in Multiple Myeloma Patients

Is BioLineRx (TLV:BLRX) Using Debt In A Risky Way?

Forecast breakeven pushed back to 2024

BioLineRx Ltd. Announces Positive Top-Line Results from GENESIS Phase 3 Trial of Motixafortide in Stem-Cell Mobilization for Autologous Bone Marrow Transplantation in Multiple Myeloma Patients